TITUSVILLE, N.J. — Janssen Scientific Affairs has debuted an new online scientific resource for U.S. healthcare professionals seeking instant access to current information about Janssen products marketed in the United States.
JanssenMD, a Web-based application is designed for use on desktops, tablets and smartphones, has search functionality that enables clinicians to easily find full prescribing information, clinical trial data and safety information about Janssen medications. It is among the first medical information websites to offer a self-service model that is accessible through mobile devices, the company said. Currently, scientific information is available for five pharmaceutical products: Edurant (rilpivirine), Remicade (infliximab), Stelara (ustekinumab), Xarelto (rivaroxaban) and Zytiga (abiraterone acetate). Additional Janssen medications soon will be added to the resource.
"JanssenMD was created to provide healthcare professionals with the information they need, when, where, and how they need it," said Norm Rosenthal, chief scientific officer at Janssen Scientific Affairs. "This unique digital platform enables us to respond to healthcare professionals' questions with information that is current, accurate, and instantly accessible from any device they are using."